The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study
Abstract
Background The evolving epidemic of type 2 diabetes has challenged health-care providers to assess the safety and efficacy of various diabetes prevention strategies. The CANOE (CAnadian Normoglycemia Outcomes Evaluation) trial investigated whether low-dose combination therapy would affect development of type 2 diabetes. Methods In this double-blind, randomised controlled trial undertaken in clinics in Canadian centres, 207 patients with impaired glucose tolerance were randomly assigned to receive combination rosiglitazone (2 mg) and metformin (500 mg) twice daily or matching placebo for a median of 3.9 years (IQR 3.0-4.6). Randomisation was computer-generated in blocks of four, with both participants and investigators masked to treatment allocation. The primary outcome was time to development of diabetes, measured by an oral glucose tolerance test or two fasting plasma glucose values of 7.0 mmol/L or greater. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00116932. Findings 103 participants were assigned to rosiglitazone and metformin, and 104 to placebo; all were analysed. Vital status was obtained in 198 (96%) participants, and medication compliance (taking at least 80% of assigned medication) was 78% (n=77) in the metformin and rosiglitazone group and 81% (n=80) in the placebo group. Incident diabetes occurred in significantly fewer individuals in the active treatment group (n=14 [14%]) than in the placebo group (n=41 [39%];…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is strong evidence that oral glucose-lowering medications approved for DM reduce the progression of prediabetes to DM.888–896”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [893]
In the citing paper
“Additionally, acarbose may be associated with reduced risk of DM891–894 as well as coronary heart disease as shown in the STOP-NIDDM trial.892”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [893]
In the citing paper
“However, these hypotheses are based on results from the Swedish Obese Subjects Study in which subjects were not randomized and the control group was contemporaneously matched, only received conventional treatment, and differed by a number of characteristics at baseline.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [175]
In the citing paper
“In the recently published CANOE trial, low doses of rosiglitazone (2 mg b.i.d.) in combination with metformin were tested against placebo to examine whether the lower doses would cause less side effects. The risk of incident diabetes was reduced by 66% in the active treatment group with no significant difference in weight gain as compared to controls. However more people complained of diarrhoea in”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [101]
In the citing paper
“In the CAnadian Normoglycemia Outcomes Evaluation (CANOE) trial, treatment with rosiglitazone 2 mg per day and metformin 500 mg twice a day combined, reduced incident diabetes 66%, an effect size larger than that observed in trials of metformin alone; however, there was no single-drug comparator arm.206”
From The Vasculature in Prediabetes (2018) · cites this paper as [206]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Pan, X.-R., Li, G.-W., Hu, Y.-H., Wang, J.-X., Yang, W.-Y., An, Z.-X., Hu, Z.-X., Juan-Lin, Xiao, J.-Z., Cao, H.-B., et al. (1997) · Diabetes Care · doi:10.2337/diacare.20.4.537 · Cited by 4,320
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Cited by
Prediabetes: a high-risk state for diabetes development
Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J., & Kivimäki, M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60283-9 · Cited by 2,958
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Type 2 diabetes across generations: from pathophysiology to prevention and management
Nolan, C. J., Damm, P., & Prentki, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60614-4 · Cited by 923
Metadata
- Authors
- Zinman, B., Harris, S. B., Neuman, J., Gerstein, H. C., Retnakaran, R. R., Raboud, J., Qi, Y., & Hanley, A. J.
- Affiliations
- Mount Sinai Hospital (CA)
- Western University (CA)
- Population Health Research Institute (CA)
- University Health Network (CA)
- Corresponding author
- Zinman, Bernard
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2010-07
- Volume
- 376
- Issue
- 9735
- Pages
- 103-111
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2134599810
- Cited by
- 235
- References
- 28
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 11 · 2023: 13 · 2022: 12 · 2021: 13 · 2020: 12 · 2019: 10 · 2018: 17 · 2017: 10 · 2016: 11 · 2015: 18 · 2014: 23 · 2013: 21 · 2012: 15
- FWCI
- 19.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Diabetes Association
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes prevention, rosiglitazone, metformin, combination therapy, impaired glucose tolerance, insulin sensitivity, insulin resistance, PPARγ agonists, number needed to treat, medication adherence, adverse events, hypoglycemia, liver enzymes, weight gain
- MeSH terms
- Rosiglitazone, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Glucose Tolerance Test, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Risk Factors, Glucose Intolerance, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. https://app.cochat.ai/papers/10.1016/s0140-6736(10)60746-5
- The paper
- Zinman, B., Harris, S. B., Neuman, J., Gerstein, H. C., Retnakaran, R. R., Raboud, J., Qi, Y., & Hanley, A. J. (2010). Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. The Lancet. https://doi.org/10.1016/s0140-6736(10)60746-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.